MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ehf2.14624

Медицинская библиотека · ESC heart failure · 2024

Pre-emptive treatment of heart failure exacerbations in patients managed with the HeartLogic™ algorithm.

Garcia Rodrigue, Gras Daniel, Mansourati Jacques, Defaye Pascal, Bisson Arnaud, Boveda Serge, Gandjbakhch Estelle, Gras Matthieu, Gueffet Jean-Pierre, Himbert Caroline, Jacon Peggy, Khattar Pierre, Lequeux Benoit, Li Anthony, Mansourati Vincent, Minois Damien, Marijon Eloi, Pierre Bertrand, Probst Vincent, Degand Bruno, HeartLogic™ France Cohort Study Investigators

СтатьяПеревод в очереди

Аннотация

AIMS: Heart failure (HF) is a chronic disease affecting 64 million people worldwide and places a severe burden on society because of its mortality, numerous re-hospitalizations and associated costs. HeartLogic™ is an algorithm programmed into implanted devices incorporating several biometric parameters which aims to predict HF episodes. It provides an index which can be monitored remotely, allowing pre-emptive treatment of congestion to prevent acute decompensation. We aim to assess the impact and security of pre-emptive HF management, guided by the HeartLogic™ index.

METHODS AND

RESULTS

The HeartLogic™ France Cohort Study is an investigator-initiated, prospective, multi-centre, non-randomized study. Three hundred ten patients with a history of HF (left ventricular ejection fraction ≤40%; or at least one episode of clinical HF with elevated NT-proBNP ≥450 ng/L) and implanted with a cardioverter defibrillator enabling HeartLogic™ index calculation will be included across 10 French centres. The HeartLogic™ index will be monitored remotely for 12 months and in the event of a HeartLogic™ index ≥16, the local investigator will contact the patient for assessment and adjust HF treatment as necessary. The primary endpoint is unscheduled hospitalization for HF. Secondary endpoints are all-cause mortality, cardiovascular death, HF-related death, unscheduled hospitalizations for ventricular or atrial arrhythmia and HeartLogic™ index evolution over time. Blood samples will be collected for biobanking, and quality of life will be assessed. Finally, the safety of a HeartLogic™-triggered strategy for initiating or increasing diuretic therapy will be assessed. A blind and independent committee will adjudicate the events.

CONCLUSIONS

The HeartLogic™ France Cohort Study will provide robust real-world data in a cohort of HF patients managed with the HeartLogic™ algorithm allowing pre-emptive treatment of heart failure exacerbations.

Для цитирования: Garcia Rodrigue, Gras Daniel, Mansourati Jacques, Defaye Pascal, Bisson Arnaud, Boveda Serge, Gandjbakhch Estelle, Gras Matthieu, Gueffet Jean-Pierre, Himbert Caroline, Jacon Peggy, Khattar Pierre, Lequeux Benoit, Li Anthony, Mansourati Vincent, Minois Damien, Marijon Eloi, Pierre Bertrand, Probst Vincent, Degand Bruno, HeartLogic™ France Cohort Study Investigators. Pre-emptive treatment of heart failure exacerbations in patients managed with the HeartLogic™ algorithm.. ESC heart failure. 2024. DOI: 10.1002/ehf2.14624.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.